Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genta, Inc. (GNTA) -- Ignore unavailable to you. Want to Upgrade?

To: Ken S. who wrote (1815)	5/14/2004 5:37:35 PM
From: Art Bechhoefer	Respond to of 1870

One missing item in recent GNTA announcements concerns testing of Genasense in patients with breast cancer--a clinical trial going on at the Andersen Cancer Center in Houston. Several months ago, a press release noted that Genasense had promising results in patients whose cancers contained the Bcl-2 factor, including breast cancer. My guess is that they are hoping that the remaining clinical trials, including breast cancer, will produce some solid results as early as August or September. I do not anticipate much before that time. I doubt that the stock will gain much, unless some other companies testing antisense drugs come up with some promising results that trigger a sympathetic reaction. Art